Justice Department subpoenas J&J over opioid policies

Oct. 29, 2019

According to Johnson & Johnson's regulatory filing earlier this week, it received a grand jury subpoenas back in August from the U.S. attorney’s office for the Eastern District of New York over its opioid medication policies.

The subpoenas were related to anti-diversion policies and procedures and the distribution of its opioid medications developed by its Janssen pharmaceuticals unit. According to J&J, the filing relates to monitoring and reporting programs by manufacturers and distributors of opioids under the Controlled Substances Act. The company claims its anti-diversion policies and procedures complied with the law.

In August, an Oklahoma judge ordered J&J to pay $572 million to the state for its part in fueling an opioid epidemic.

Read the Reuters report